Evidence map›Paper›PMID 35149932›Full record

ArticleEndocrine2022

Prolonged survival of anaplastic thyroid carcinoma is associated with resectability, low tumor-infiltrating neutrophils/myeloid-derived suppressor cells, and low peripheral neutrophil-to-lymphocyte ratio.

Bin Xu, Lingxin Zhang, Reza Setoodeh, Abhinita S Mohanty, Iñigo Landa, Bonnie Balzer, Vera Tiedje, Ian Ganly, Snjezana Dogan, James A Fagin and 1 more

Open access · greenAbstract read
In one paragraph

Article in Endocrine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. TCIRG1BMC oral health · 2026
    Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Bin XuDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. xub@mskcc.org.ORCID 0000-0003-4638-9835
Lingxin ZhangDepartment of Pathology, Mount Sinai Hospital, Toronto, Ontario, Canada.
Reza SetoodehDepartment of Pathology, Cedar Sinai Medical Center, Los Angeles, CA, USA.
Abhinita S MohantyDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Iñigo LandaDepartment of Medicine, Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
Bonnie BalzerDepartment of Pathology, Cedar Sinai Medical Center, Los Angeles, CA, USA.
Vera TiedjeDivision of Subspecialty Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ian GanlyDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Snjezana DoganDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
James A FaginDivision of Subspecialty Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ronald GhosseinDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Memorial Sloan Kettering Cancer Center · USCedars-Sinai Medical Center · USBrigham and Women's Hospital · USMount Sinai Hospital · CA

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Targeting immune suppressive microenvironment in ATCR01CA255211 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI FAGIN, JAMES A · 2021 to 2025
$2.2M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA255211
6 · The paper itself

Abstract

purposeAnaplastic thyroid carcinoma (ATC) is the most lethal form of thyroid cancer with most patients dying of their disease within a few months. Only a very small percentage of long-term survivors (LTS) are alive for 2 years or longer. In this retrospective case-control study, we provided a comprehensive comparison between 46 ATC LTSs and 75 ATC control patients who suffered disease-specific mortality within 2 years, aiming to identify factors that may be associated with prolonged survival in ATC.

methodsA comprehensive clinicopathologic and molecular comparison was performed between 46 ATC LTSs and 75 ATC control patients. Peripheral neutrophil count and neutrophil-to-lymphocyte ratio (NLR) were recorded. The composition of the tumor microenvironment was compared using immunohistochemistry.

resultsCompared with ATC control patients, ATC LTSs were characterized by 1) higher frequency of (primary) resection as well as clinicopathologic parameters attributed to resectability; 2) lower rate of concurrent RAS/BRAF and TERT promoter mutations; 3) lower peripheral neutrophil count and NLR; and 4) lower number of tumor-infiltrating neutrophils/myeloid-derived suppressor cells (MDSC). The survival benefits of low peripheral neutrophil counts and low NLR persisted even when controlling for distant metastasis status at presentation.

conclusionsIn addition to traditional beneficial prognostic factors, e.g., surgical resection, factors attributed to resectability, and absence of co-existing RAS/BRAF and TERT promoter mutations, we herein show that tumor-infiltrating and circulating neutrophils/MDSC are adverse prognostic factors in ATC.

Indexed as

Myeloid-Derived Suppressor CellsThyroid Carcinoma, AnaplasticThyroid NeoplasmsCase-Control StudiesHumansLymphocytesNeutrophilsPrognosisProto-Oncogene Proteins B-rafRetrospective StudiesTumor MicroenvironmentProto-Oncogene Proteins B-rafAnaplastic thyroid carcinomaMyeloid-derived suppressor cells (MDSC)Neutrophil-to-lymphocyte ratio (NLR)PrognosisTumor-infiltrating neutrophils

Identifiers

PMID35149932
PMCPMC10173871
OpenAlexW4211123060

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.